TY  - JOUR
AU  - Sparber-Sauer, Monika
AU  - Vokuhl, Christian
AU  - Seitz, Guido
AU  - Sorg, Benjamin
AU  - Tobias, Möllers
AU  - von Kalle, Thekla
AU  - Münter, Marc
AU  - Bielack, Stefan S
AU  - Ladenstein, Ruth
AU  - Ljungman, Gustaf
AU  - Niggli, Felix
AU  - Frühwald, Michael
AU  - Loff, Stefan
AU  - Klingebiel, Thomas
AU  - Koscielniak, Ewa
TI  - Infantile myofibromatosis: Excellent prognosis but also rare fatal progressive disease. Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry.
JO  - Pediatric blood & cancer
VL  - 69
IS  - 3
SN  - 1545-5009
CY  - New York, NY
PB  - Wiley
M1  - DKFZ-2021-02243
SP  - e29403
PY  - 2022
N1  - Volume69, Issue3, March 2022, e29403
AB  - Infantile myofibromatosis (IM) is a rare benign soft tissue tumor and often a self-limiting disease but rarely includes life-threatening complications. Little is known about optimal treatment of primary localized (LD) and multifocal disease (MFD).Treatment and outcome of 95 children with IM registered within five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry (1981-2016) were evaluated.LD was diagnosed in 71 patients at a median age of 0.4 years (range 0.0-17.7). MFD was present in 24 patients. The mainstay of treatment was watch-and-wait strategy (w</td><td width="150">
AB  - w) after initial biopsy or resection. Low-dose chemotherapy (CHT) was administered to 16/71 (23
KW  - CWS Group (Other)
KW  - infantile myofibromatosis (Other)
KW  - infants and children (Other)
KW  - localized and multifocal disease (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:34636137
DO  - DOI:10.1002/pbc.29403
UR  - https://inrepo02.dkfz.de/record/177013
ER  -